Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - ImVisioN Therapeutics Inc. - Exhibit 10.20

IMVISION THERAPEUTICS INC. 
Feodor-Lynen Strasse 5,
Hanover, Germany 
Tel: 011 49 511 53 88 96-76 
Fax: 011 49 511 53 88
96-66 

EXHIBIT 10.20 

November 7, 2006 

TO THE UNDERSIGNED SHAREHOLDER OF 
IMVISION THERAPEUTICS
INC. 

Dear Sirs: 

	
      Restricted Stock Purchase Agreement dated ________________________,
        2006 between ImVisioN Therapeutics Inc. (the “Company”)
        and the undersigned shareholder of the Company (the “Restricted
        Stock Purchase Agreement”) 

We write further to the Restricted Stock Purchase Agreement and
  the registration statement on Form SB-2 (the “Initial Registration Statement”)
  filed by the Company with the United States Securities and Exchange Commission
  (the “SEC”) pursuant to the United States Securities Act of 1933 (the
  “1933 Act”) which included the registration of the resale by the Shareholder
  of ________ shares of the Company’s common stock (the “Registration
  Shares”) pursuant to the 1933 Act. 

We confirm our agreement as follows: 

	
  The Initial Registration Statement will be amended to remove the
  Registration Shares from the Initial Registration Statement; and 

  
	
  Upon release of the Registration Shares from escrow in accordance with the
  terms and conditions of the Restricted Stock Purchase Agreement, the Company
  will file a further registration statement with the SEC in order to register
  the resale by the Shareholder of the Registration Shares under the 1933 Act
  (the “New Registration Statement”) upon receipt of a written demand for
  registration from the Shareholder (a “Registration Demand”). Upon receipt of a
  Registration Demand, the Company will use its reasonable best efforts to
  prepare and file the New Registration Statement with the SEC as soon as
  possible and in no event later than 30 days of receipt of the Registration
  Demand. Upon filing of the Registration Statement, the Company will use its
  reasonable best efforts to cause the Registration Statement to be declared
  effective by the SEC as early as possible. The Company will maintain the New
  Registration Statement in effect until such time as the Shareholder can sell
  all Registration Shares without registration in reliance of Rule 144 of the
  1933 Act. 

Please execute and return a copy of this letter to confirm your
agreement. 

Yours sincerely, 

ImVisioN Therapeutics Inc.

Per: 

________________________________
Dr. Martin Steiner,
President and CEO 

Agreed and accepted by the undersigned shareholder effective
the ____ day of November, 2006. 

	Signature of Shareholder 	 
	 	 
	Name of Shareholder:Filed by Automated Filing Services Inc. (604) 609-0244 - ImVisioN Therapeutics Inc - Exhibit 10.21

RCC 
Linking Science to progress 

EXHIBIT 10.21 

RCC Ltd. 
Zelgliweg 1

4452 ltingen 
Switzerland 
Phone     +41 61 975 11
11 
Fax          +41 61 971 52
84 

STUDY CONTRACT 

between 

ImVisioN GmbH, Prof. Dr. Horst Rose

Feodor-Lynen-Strasse 5, 30625 Hannover/Germany 

________________________________________________________________________________________________
(in
the following referred to as the Client) 

Contact Person: Prof. Dr. Stefan W. Hockertz, tpi Consult GmbH,
Seelze / Germany 

and 

RCC Ltd, CH-4452 ltingen/BL,
Switzerland
________________________________________________________________________________________________
(in
the following referred to as the RCC) 

Contact Person for this Contract at RCC: Dr. Rai Blumbach 

RCC Study Number: A99270 of October 18, 2006 

 

Test item name: IVN 201 

The contracted studies will (where applicable) be carried out
in accordance with the respective guidelines and in conformity with the
principles for “Good Laboratory Practices” (GLP). 

RCC 

  Linking Science to progress 

Contracted Studies 

The Client herewith commissions the following studies to RCC.

RCC Study Number A99270 

57-day Toxicity Study, intranodal, mouse, Pharmaceuticals

Scientific Contact: Dr. Kai Blumbach 

Study Outline 

	Number of animals 	80 mice,4 groups of 10/10 for
      toxicity testing 
	  	40 mice,4 groups of 5/5 for
      immunotoxicity testing 
	  	50 mice, group 4 with 19/19 mice
      and group 1 with 6/6 mice for 
	  	toxicokinetics/exposure check
  
	Accommodation 	Individual housing 
	Acclimatization 	At least 5 days, usually 7 days
    
	Administration 	Intranodal, every two weeks, 5
      times points 
	Mortality 	Twice daily 
	Clinical signs 	Daily cage-side clinical
      observations (twice on days 1-3 and once on 
	  	days 4-56 
	Food consumption 	Weekly 
	Body weight 	Weekly 
	Toxicokinetics 	Group 1 (control): 
	  	3 samples/sex, 2 intervals/day in
      weeks 1 and 8 
	  	Group 4: 
	  	3 samples/sex, 5 intervals/day in
      weeks 1 and 8 and 
	  	4 samples/sex, 1 interval/day in
      weeks 1 and 8 
	  	Number of samples: 100
  
	  	Number of TK-curves: 4
      (the control group will be used f or exposure 
	  	check only, no curves will be
      evaluated) 
	Clinical pathology 	Hematology (5/5 animals per
      dose), clinical biochemistry (5/5 animals 
	  	per dose) and urinalysis (pooled
      urine samples from 5/5 animals per 
	  	dose) in all toxicity testing
      animals after week 6 and at necropsy. 
	Pathology 	Necropsy (all toxicity testing
      animals), organ weights (according to 
	  	guidelines). Histopathology
      examination of the collected organs/tissues 
	  	in all animals of groups 1 and 4
      and in all animals, which were 
	  	sacrificed or died spontaneously
      during the study. All gross lesions of 
	  	all animals will be evaluated
      histopathologically. Necropsy of all 
	  	toxicokinetics animals, samples
      of liver, spleen, lymph nodes, brain, 
	  	kidneys, lungs and bone marrow
      will be frozen in liquid nitrogen and 
	  	sent to the sponsor on dry ice),
    
	GLP 	Fully GLP compliant 
	Price of the Study 	€ 155'000.--

	RCC Study A99270 of October 18, 2006 / bon 	2/5 
	1359073.1 	  

RCC 

  Linking Science to progress 

General 

The prices do not include VAT and are applicable for test items
where common safety precautions and treatments are sufficient. 

Schedule 

The studies will be planned individually and initiated after
receipt of the signed study contract, the test item and all necessary test item
information (Data Sheet, analytical method etc.) 

Capacity Reservation 

RCC reserves herewith the necessary capacity for the above
mentioned studies. The Client will provide the test item and the necessary test
item information on time. 

Terms of Payment 

50% at start of the study 
40% on delivery of the draft
report 
10% plus final account on delivery of the final report or latest
eight weeks after delivery of the draft report. 

Invoice Address 

ImVisioN GmbH Prof. 
Dr. Horst Rose 
Feodor-Lynen-Strasse
5 
30625 Hannover 
Germany 

Standard Conditions 

The Standard Conditions of RCC form an integral part of this
study contract. 

	RCC Ltd 	 	  	 	For the Client 
	 	 	 	 	 
	/s/ Dr. Kai
      Blumbach 	 	/s/
      Dr. Kerstin Broich 	 	/s/
      Prof. Dr. Horst Rose 
	Dr. Kai Blumbach 	 	Dr. Kerstin Broich 	 	Prof. Dr. Horst Rose 
	Head of Subchronic 	 	Study Director 	 	  
	Rodent Toxicology 	 	Rodent Toxicology 	 	  
	 	 	 	 	 
	Date: October 18, 2006 	 	  	 	Date: 31 Oct. 2006 

	RCC Study A99270 of October 18, 2006 / bon 	3/5 
	1359073.1EXHIBIT 4.1
                                                                     -----------

NOTE, AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF, HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS AND MAY NOT BE REOFFERED, SOLD, TRANSFERRED, PLEDGED, OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (1) REGISTRATION UNDER SUCH ACT OR LAWS
OR (2) AN OPINION OF COUNSEL FOR THE COMPANY OR OTHER COUNSEL REASONABLY
ACCEPTABLE TO THE COMPANY TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED.

                             SEMOTUS SOLUTIONS, INC.
                           CONVERTIBLE PROMISSORY NOTE

$225,000                                                       13 November, 2006

FOR VALUE RECEIVED, Semotus Solutions, Inc., a Nevada corporation (the
"Company"), promises to pay to the order of Richard J. Sullivan (the "Payee"),
at the office of the Payee at 777 South Flagler Drive, Suite 800 West Tower,
Palm Beach, FL 33401-6161, or at such other place as Payee may designate in
writing, the principal sum of Two Hundred Twenty Five Thousand Dollars
($225,000) (the "Principal Amount") on the terms set forth below. Interest on
the unpaid principal balance shall accrue at a rate of eight percent (8%) per
annum, from 13 November, 2006 with respect to the Principal Amount. All payments
of interest and principal hereunder shall be made in placecountry-regionU.S.
currency.

     This Note is made in connection with that certain Investment Agreement
dated November 13, 2006 between Company and Payee (the "Investment Agreement").

         1. DEFINITIONS.

Capitalized terms not defined herein shall have the same meaning as set forth in
the Investment Agreement. The following terms shall have the meanings herein
specified:

     "Capital Stock" means any of the current or future authorized class or
series of capital stock of the Company.

     "Common Stock" means authorized Common Stock, $.01 par value, of the
Company, and shall include any other class or series of capital stock of the
Company that is not limited to a fixed sum in respect of the rights of the
holder thereof to participate in the liquidation or winding up of the Company.

     "Conversion Notice" shall have the meaning set forth in Section 2(a).

     "Conversion Price" shall mean the per share price(s) at which some or all
of the Principal Amount plus all accrued interest thereon is converted or
convertible pursuant to Section 2, and in all cases as adjusted pursuant to
Section 2(e).

                                       1
<PAGE>

     "Conversion Shares" means the shares of Capital Stock, issuable upon
conversion of this Note.

     "Event of Default" means an event specified in Section 4 hereof.

     "Holder" means the Payee, and each endorsee, pledgee, assignee, owner and
holder of this Note, as such; and any consent, waiver or agreement in writing by
the then Holder with respect to any matter or thing in connection with this
Note, whether altering any provision hereof or otherwise, shall bind all
subsequent Holders. Notwithstanding the foregoing, the Company may treat the
registered holder of this Note as the Holder for all purposes.

     "Principal Amount" shall have the meaning set forth in the initial
paragraph.

     "Person" means an individual, trust, partnership, firm, association,
corporation or other organization or a government or governmental authority.

          Words of one gender include the other gender; the singular includes
the plural; and the plural includes the singular, unless the context otherwise
requires.

         2. CONVERSION OF THE NOTE.

(a) Election to Convert. Holder may, at its option, exercise by written notice
(the "Conversion Notice") to the Company at any time prior to payment in full
hereof, elect to convert all or any part of the entire outstanding principal
amount of this Note plus a pro rata share of the accrued interest on the then
outstanding balance into Common Shares at a conversion price equal to ten cents
($0.10) per share, which equals Two Million, Two Hundred Fifty Thousand,
(2,250,000) shares (subject to adjustment in the event of any stock splits,
stock dividends or other recapitalization of Common Shares).

 (b) Delivery of Conversion Shares. The Capital Stock issued on conversion of
this Note (the "Conversion Shares") shall be delivered as follows:

         As promptly as practicable after conversion, the Company shall deliver
to Holder, or to such person or persons as are designated by Holder in the
Conversion Notice, a certificate or certificates representing the number of
shares of Capital Stock into which this Note or portion thereof is to be
converted in such name or names as are specified in the Conversion Notice,
rounded to the nearest whole share. Such conversion shall be deemed to have been
effected at the close of business on the date when this Note shall

                                       2
<PAGE>

have been surrendered to the Company for conversion, so that the person entitled
to receive such Conversion Shares shall be treated for all purposes as having
become the record holder of such Conversion Shares at such time.

         In the event that less than the entire outstanding principal of this
Note is converted hereunder pursuant to subsection (a) above, this Note shall
not be surrendered for cancellation but shall have the fact and amount of
conversion recorded on the face of this Note by writing acknowledged by Holder
and the Company. If less than the entire principal balance of this Note is
converted, the amount of principal converted shall be reduced to the nearest
amount that results in no fractional shares.

(c) Reservation of Shares. The Company agrees that, during the period within
which this Note may be converted, the Company will, at all times, have
authorized and in reserve, and will keep available solely for delivery upon the
conversion of this Note, Capital Stock and other securities and properties as
from time to time shall be receivable upon the conversion of this Note, free and
clear of all restrictions on issuance, sale or transfer other than those imposed
by law and free and clear of all pre-emptive rights. The Company agrees that the
Conversion Shares shall, at the time of such delivery, be validly issued and
outstanding, fully paid and non-assessable, and the Company will take all such
action as may be necessary to assure that the stated value or par value per
share of the Conversion Shares is at all times equal to or less than the
Conversion Price.

(d) Registration of Conversion Shares. The Company agrees to file a registration
statement within 60 days of conversion of this Note that includes all of the
Conversion Shares.

(e) Protection Against Dilution.

         (i) In the event of any consolidation with or merger of the Company
with or into another corporation (other than a merger or consolidation in which
the Company is the surviving or continuing corporation) or any sale, lease or
conveyance to another corporation of the property of the Company as an entirety
or substantially as an entirety, in either case while any principal or accrued
interest remains outstanding under this Note, then such successor, leasing or
purchasing corporation, as the case may be, shall

              (1) execute with the Holder an agreement providing that the Holder
         shall have the right thereafter to receive upon conversion of this Note
         solely the kind and amount of shares of stock and other securities,
         property, cash or any combination thereof receivable upon such
         consolidation, merger, sale, lease or conveyance by a holder of the
         number of shares of Capital Stock for which this Note might have been
         converted immediately prior to such consolidation, merger, sale, lease
         or conveyance,

              (2) make effective provision in its articles of association or
         otherwise, if necessary, in order to effect such agreement, and

                                       3
<PAGE>

              (3) set aside or reserve, for the benefit of the Holder, the
         stock, securities, property and cash to which the Holder would be
         entitled upon conversion of this Note.

         (ii) In the event of any reclassification or change of the Capital
Stock into which this Note may be converted (other than a change in par value or
from no par value to a specified par value, or as a result of a subdivision or
combination, but including any change in the shares into two or more classes or
series of shares), or in the event of any consolidation or merger of another
corporation into the Company in which the Company is the continuing corporation
and in which there is a reclassification or change (including a change to the
right to receive cash or other property) of the Capital Stock into which this
Note may be converted (other than a change in par value, or from no par value to
a specified par value, or as a result of a subdivision or combination, but
including any change in the shares into two or more classes or series of
shares), in either case while any principal or accrued interest remains
outstanding under this Note, then the Holder shall have the right thereafter to
receive upon conversion of this Note solely the kind and amount of shares of
stock and other securities, property, cash or any combination thereof receivable
upon such reclassification, change, consolidation or merger by a holder of the
number of shares of Capital Stock for which this Note might have been converted
immediately prior to such reclassification, change, consolidation or merger.

         (iii) If the Capital Stock shall be recapitalized or reclassified or
the Company shall effect any stock dividend, stock split, or reverse stock split
of the Capital Stock, then the Conversion Shares to be issued shall be
proportionately and equitably adjusted to reflect any increase or decrease in
the number of Conversion Shares resulting from such corporate event.

         3. PAYMENT OF THIS NOTE - PRINCIPAL AND INTEREST.

(a) Payment after Milestone Deadline. All principal and interest that has not
been converted into Capital Stock pursuant to Section 2 above shall be due and
payable on November 1, 2008 and, at any time thereafter, the Holder may proceed
to collect such unconverted principal and accrued interest.

(b) Payment on an Event of Default. If an Event of Default occurs and is
continuing, then the Holder of this Note may, by written notice to the Company,
declare this Note immediately due and payable and demand payment of all
principal and interest that has not been converted into Common Stock pursuant to
Section 2 above, and, at any time thereafter, the Holder may proceed to collect
such unconverted principal and accrued interest.

(c) Prepayment. The Company may prepay this Note at any time after six months
after the date hereof; provided that, prior to on or before May 1, 2007, the
Company shall give Holder at least 30 days' advance written notice, and after
May 1, 2007, the Company

                                       4
<PAGE>

shall give Holder at least 15 days' advance written notice, of the Company's
intent to prepay and Holder shall have the right to convert all or any portion
of this Note pursuant to Section 2(b) at any time during such 30-day or 15-day
period, as applicable.

         4. EVENTS OF DEFAULT.

The existence of any of the following conditions shall constitute an Event of
Default:

(a) Commencement of proceedings under any bankruptcy or insolvency law or other
law for the reorganization, arrangement, composition or similar relief or aid of
debtors or creditors if such proceeding remains undismissed and unstayed for a
period of 60 days following notice to the Company by the Holder.

(b) If the Company shall dissolve, liquidate or wind up its affairs or sell
substantially all of its assets.

(c) If the Company breaches any of its representations, warranties, covenants or
agreements set forth in the Investment Agreement and such breach shall not be
cured within 30 days after written notice thereof shall have been given to the
Company by the Holder.

(d) One or more final judgments are entered against the Company involving
aggregate unpaid liability not covered by insurance in excess of $1,000,000, and
such amounts are not paid in full within 30 days.

(e) Attachment or similar process of execution is levied against a material
portion of the Company's assets and such process is not terminated and any
orders issued pursuant thereto canceled within 90 calendar days.

(f) The Company is in material breach of any provision of this Note, which
breach (other than a breach described in Section 4(a) above) continues for more
than 30 calendar days following notice to the Company by the Holder.

         5. TRANSFER.

(a) Transfer of this Note shall be subject to prior delivery by the proposed
transferee to the Company of an opinion of counsel that such transfer is in
compliance with all federal and all applicable securities laws. In order to
transfer this Note, the Holder, or its duly authorized attorney, shall surrender
this Note at the office of the Company pursuant to Section 10 herein,
accompanied by an assignment duly executed by the Holder hereof.

(b) This Note is, and each certificate representing Conversion Shares shall be,
stamped or otherwise imprinted with a legend substantially in the following
form:

                                       5
<PAGE>

         "The securities represented hereby have not been registered under the
         Securities Act of 1933, as amended or applicable state securities laws
         and may not be reoffered, sold, transferred, pledged, or otherwise
         disposed of except pursuant to
          (1) registration under such act or laws or (2) an opinion of counsel
         for the Company or other counsel reasonably acceptable to the Company
         to the effect that such registration is not required."

         6. LOSS OR MUTILATION OF NOTE.

Upon receipt by the Company of evidence satisfactory to the Company of the loss,
theft, destruction or mutilation of this Note, together with an indemnity
reasonably satisfactory to the Company, in the case of loss, theft, or
destruction, or the surrender and cancellation of this Note, in the case of
mutilation, the Company shall execute and deliver to the Holder a new Note of
like tenor and denomination as this Note.

         7. HOLDER NOT SHAREHOLDER.

This Note does not confer upon the Holder any right to vote or to consent or to
receive notice as a shareholder of the Company, as such, in respect of any
matters whatsoever, or any other rights or liabilities as a shareholder, prior
to the conversion hereof.

         8. WAIVERS.

The failure of Holder to enforce at any time any of the provisions of this Note
shall not, absent an express written waiver signed by Holder specifying the
provision being waived, be construed to be a waiver of any such provision, nor
in any way to affect the validity of this Note or any part hereof or the right
of Holder thereafter to enforce each and every such provision. No waiver of any
breach of this Note shall be held to be a waiver of any other or subsequent
breach.

         9. TAXES.

The Holder agrees that it will pay, when due and payable, any and all stamp,
original issue or similar taxes which may be payable in respect of the issue of
this Note and/or any Conversion Shares or certificates therefor. The Company
shall not be required to pay any stamp, original issue or similar tax which may
be payable in respect of any transfer involved in the transfer and delivery of
stock certificates to a person other than of the Payee.

         10. NOTICES.

All notices or other communications to a party required or permitted hereunder
shall be in writing and shall be delivered personally or by facsimile (receipt
confirmed electronically) to such party (or, in the case of an entity, to an
executive officer of such party) or shall be sent by a reputable express
delivery service or by certified mail, postage prepaid with return receipt
requested, addressed as follows:

                                       6
<PAGE>

if to Payee to:
Richard J. Sullivan
777 South Flagler Drive,
Suite 800 West Tower,
West Palm Beach, FL 33401-6161

with a copy to:
Jody Walker
7841 South Garfield Way
Centennial, CO 80122

if to the Company to:
Tony LaPine
Semotus Solutions, Inc.
718 University Avenue, Suite 202
Los Gatos, CA 95032

     Any party may change the above specified recipient and/or mailing address
by notice to all other parties given in the manner herein prescribed. All
notices shall be deemed given on the day when actually delivered as provided
above (if delivered personally or by facsimile, provided that any such facsimile
is received during regular business hours at the recipient's location) or on the
day shown on the return receipt (if delivered by mail or delivery service).

         11. HEADINGS.

The titles and headings to the Sections herein are inserted for the convenience
of reference only and are not intended to be a part of or to affect the meaning
or interpretation of this Note. This Note shall be construed without regard to
any presumption or other rule requiring construction hereof against the party
causing this Note to be drafted.

                                       7
<PAGE>

         12. APPLICABLE LAW AND JURISDICTION.

The legality, validity, enforceability and interpretation of this Note and the
relationship of the parties hereunder shall be governed by the laws of the State
of California, without giving effect to the principles of conflict of laws,
except with respect to matters of law concerning the internal corporate affairs
of any corporate entity which is a party to or the subject of this Agreement,
and as to those matters the law of the jurisdiction under which the respective
entity derives its powers shall govern. Any claim, cause of action, suit or
demand allegedly arising out of or related to this Note, or the relationship of
the parties, shall be brought exclusively in the state or federal courts located
in Santa Clara County, California, and the parties irrevocably consent to the
exclusive jurisdiction and venue of such courts and waive any objections they
may have at any time to such exclusive jurisdiction and venue.

IN WITNESS WHEREOF, Semotus Solutions, Inc. has caused this Convertible
Promissory Note to be signed in its name by the signature of its duly authorized
representative.

SEMOTUS SOLUTIONS, INC.

/s/ Anthony LaPine
-----------------------
By: Anthony LaPine
Its: Chairman

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]